Connect your AI

Upstream Bio, Inc. UPB Total Liabilities

Total Liabilities at other companies

Regeneron PharmaceuticalsREGN

$9.45B+15.8%

Aclaris TherapeuticsACRS

$55.07M+1.9%

Shattuck Labs, Inc.STTK

$6.29M-34.4%

SavaraSVRA

$45.61M+10.0%

Avalo TherapeuticsAVTX

$31.57M+98.4%

AmgenAMGN

——

Other financials

Income statement

Revenue$1.0M+82.7%

Operating income-$43.6M-36.2%

Net income-$40.6M-48.8%

EPS (diluted)-$0.75-47.1%

Balance sheet

Cash & equivalents$96.7M+35.6%

Total debt$1.1M-34.5%

Total equity$304.0M-31.8%

Total assets$318.1M-30.3%

Cash flow

Operating cash flow-$47.9M-16.2%

CapEx$54.0K-70.8%

Free cash flow-$30.7M-55.0%

Valuation

Market cap$346.11M-40.9%

Enterprise value$250.5M-51.4%

P/S104.2×-151×

Profitability

Operating margin-5,176.5%+1,764pp

Net margin-4,719%+2,752pp

Returns & leverage

Return on equity-41.8%—

Debt / equity0×0.0×

Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Upstream Bio, Inc.'s total liabilities?: Upstream Bio, Inc. (UPB) reported total liabilities of $14.06M in Q1 2026.
How has Upstream Bio, Inc.'s total liabilities changed year-over-year?: Upstream Bio, Inc.'s total liabilities increased by 33.1% year-over-year, from $10.56M to $14.06M.
What is the long-term trend for Upstream Bio, Inc.'s total liabilities?: Over 2 years (2023 to 2025), Upstream Bio, Inc.'s total liabilities has grown at a 22.1% compound annual growth rate (CAGR), from $9.39M to $14M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.